Obagi Medical Products` CLENZIderm M.D. Serum Gel Significantly Reduces Non-Inflammatory Lesions with Visible Results as Early as Week One

Final Data from a 12-Week Study Shows a Significant Reduction in
Non-Inflammatory Lesions with the Use of CLENZIderm M.D. Serum Gel vs.
Combination Prescription BPO/Clindamycin Product
BOSTON--(Business Wire)--
Today Obagi Medical Products, Inc. (Nasdaq:OMPI), the leader in topical
aesthetic and therapeutic skin health systems, announced the successful
completion of a 12-week study comparing CLENZIderm M.D.TM Serum Gel to a leading
combination prescription benzoyl peroxide (BPO)/clindamycin product. The
announcement was made at the American Academy of Dermatology`s (AAD) Summer
Academy Meeting in Boston, MA. Of the 65 enrolled patients, 23 received four
weeks of treatment (100 percent compliance) and 42 received 12 weeks of
treatment (88 percent compliance). The data of the multicenter,
investigator-blind, randomized, split-face study shows that patients with
moderate facial acne vulgaris experienced significantly greater reductions in
non-inflammatory lesions when using the CLENZIderm M.D. Serum Gel when compared
to the leading topical BPO/clindamycin product.

"The use of CLENZIderm M. D. Serum Gel in this study resulted in faster onset of
results, showing a greater reduction in non-inflammatory lesions in weeks one
through four. In treating a disease like acne that can cause significant
emotional distress, I want to treat my patients with a product that I know will
give them rapid improvement," says investigator Leon Kircik, MD, of Physicians
Skin Care in Louisville, Kentucky, and fellow of the American Academy of
Dermatology. "Results of the study also showed continued improvement through
week 12 with the use of CLENZIderm M.D. Serum Gel."

"The results of this study indicate that Obagi Medical Products` novel
solubilized BPO technology may improve the treatment options available for the
17 million acne patients in the U.S.," says James P. Hartman, Vice President of
Marketing for Obagi Medical Products. "With the growing issue of antibiotic
resistance, creating this technology that penetrates the follicle and reduces
acne flare-ups quickly and effectively without the need for antibiotics allows
OMP to offer an alternative in the treatment of acne."

Study Methodology

Participants in the comparison study ranged in age from 11-45 years of age and
exhibited moderate facial acne vulgaris (25-100 non-inflammatory lesions, 25-100
inflammatory lesions and up to 2 nodulocystic lesions on the face). Patients
applied CLENZIderm M. D. Serum Gel to one facial side and the BPO/clindamycin
product on the contralateral side, twice daily for the duration of the study. Of
the 23 subjects enrolled in the 4-week study, all completed the study. Of the 42
subjects enrolled in the 12-week study, 37 (88%) completed the study.

During the first four weeks of treatment, reductions in non-inflammatory lesion
count were significantly greater with the CLENZIderm M.D. Serum Gel regimen than
the BPO/clindamycin regimen. The reduction in inflammatory lesion count was
comparable in both groups throughout the study. At the close of the 12-week
study the area treated with CLENZIderm M.D. Serum Gel showed a 57 percent
reduction versus a 46 percent reduction in non-inflammatory lesions on the area
treated with BPO/clindamycin. Levels of patient satisfaction, based on
improvement in their acne, erythema, dryness, peeling, stinging/burning and
itching, were comparable in both groups.

NON-INFLAMMATORY LESIONS
TREATMENT WEEK 1 REDUCTION WEEK 4 REDUCTION WEEK 12 REDUCTION
5% Solubilized BPO serum gel 26% (P≤ .05) 42% 57%
5% BPO/1% clindamycin 3% 28% 46%

About Solubilized Benzoyl Peroxide

OMP`s proprietary, solubilized BPO, leveraging SoluZyl Technology, is 1/10,000
the size of any other benzoyl peroxide molecule available, so it can penetrate
deep into the root of the follicle and treat acne where it starts. Obagi
Medical`s solubilized 5% BPO is clinically proven to kill more P. acnes bacteria
faster than the leading gel BPO/antibiotic combination product.

The solubilized BPO is available in both gel and lotion forms and can be
purchased individually or as part of a CLENZIderm M.D. Acne Therapeutic System.
The Systems come in two formulations, one for normal to oily skin patients (Gel)
and one for normal to dry skin patients (Lotion).

The CLENZIderm M.D. Systems are not available over the counter and can only be
obtainedthrough physician offices.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the
dermatology, plastic surgery, and related aesthetic markets. Using its
Penetrating Therapeutics technologies, Obagi Medical's products are designed to
improve penetration of agents across the skin barrier for common and visible
skin conditions in adult skin including chloasma, melasma, senile lentigines,
acne vulgaris and sun damage. The history of Obagi's skin care product
introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only
prescription-strength vitamin C and hydroquinone system), 2004; Obagi
Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Condition
and Enhance for use with cosmetic procedures to enhance patient outcomes and
satisfaction, 2006; Obagi ELASTIderm eye treatment and Obagi CLENZIderm M.D.
acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm M.D. Systems
for normal to dry skin, June 2007; and Obagi ELASTIderm Décolletage System,
January 2008 and Obagi Rosaclear System in January 2009. Visit www.obagi.com for
information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified
by the use of forward-looking terminology such as the words "believes,"
"expects," "may," "will," "should," "potential," "anticipates," "plans," or
"intends" and similar expressions. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause actual
results, events or developments to be materially different from the future
results, events or developments indicated in such forward-looking statements.
Such factors include, but are not limited to the intense competition our
products face and will face in the future, the level of market acceptance of our
products, the possibility that our products could be rendered obsolete by
technological or medical advances, the possibility that we may become involved
in intellectual property claims and litigation that could adversely affect the
profitability of or our ability to sell our products, the possibility that our
products may cause undesirable side effects and the fact that our ability to
commercially distribute our products may be significantly harmed if the
regulatory environment governing our products changes. A more detailed
discussion of these and other factors that could affect results is contained in
our filings with the U.S. Securities and Exchange Commission, including our Form
10-K for the year ended December 31, 2008. These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements. No assurance can be given that the future results
covered by the forward-looking statements will be achieved. All information in
this press release is as of the date of this press release and Obagi Medical
Products does not intend to update this information.

PressContact:
Creative Media Marketing
Lori Tomonari, 212-979-8884
LoriT@cmmpr.com
or
Investor Relations Contact:
OMP, Inc.
Preston Romm, Chief Financial Officer
562-256-1007

Copyright Business Wire 2009

http://www.businesswire.com/news/home/20090730005231/en